Bombay High Court Rules in Favor of Blue Cross Laboratories
In a significant ruling, the Bombay High Court has issued a permanent injunction against Alto Healthcare Pvt Ltd, preventing them from using the trademark ‘MEFIAL-SPAS’ for their pain-relief medication. The court found this mark to be deceptively similar to Blue Cross Laboratories Pvt Ltd’s renowned trademark ‘MEFTAL-SPAS’. The decision underscores the importance of protecting well-established trademarks from potential infringement and confusion in the marketplace.
Case Background and Court Findings
In the case of Blue Cross Laboratories Pvt Ltd v. Alto Healthcare Pvt Ltd, the court was presided over by Justice Arif S Doctor. The ruling emphasized that the name, packaging, and overall presentation of Alto Healthcare’s product closely resembled Blue Cross’s ‘MEFTAL-SPAS’ to such an extent that it could mislead consumers, pharmacists, and even medical professionals into believing that the two were from the same manufacturer.
Justice Doctor remarked, “Blue Cross has demonstrated the visual, phonetic, and deceptive similarity between its marks and artistic work. Products are clearly an imitation of its products, and there exists a likelihood of confusion and deception amongst the rival products, and such confusion is likely to cause consumers to purchase Alto’s product and thereby cause loss to Blue Cross.”
Trademark Infringement Evidence
Blue Cross had initiated legal proceedings for infringement of its registered trademarks ‘MEFTAL’ and ‘MEFTAL-SPAS’, as well as the registered copyright in the ‘MEFTAL-SPAS’ strip artwork. The company presented extensive evidence of its long-standing sales both domestically and internationally, supported by affidavits from company officers and sales documentation.
The court observed that Alto’s ‘MEFIAL-SPAS’ had only altered one letter from ‘MEFTAL-SPAS’, replacing ‘T’ with ‘I’, which constituted a clear case of imitation. Justice Doctor noted, “There can be no manner of doubt that the visual, phonetic, and deceptive similarity between the products and the impugned products demonstrate that Alto’s have blatantly imitated Blue Cross’ products.”
More Read
Visual and Packaging Similarities
The court highlighted that Alto Healthcare’s product also mimicked the color scheme, trade dress, and geometric border used by Blue Cross, further increasing the likelihood of confusion among consumers and industry professionals. The court’s findings supported a strong case of both trademark infringement and passing off by Alto Healthcare.
Legal Consequences and Costs
Justice Doctor criticized Alto’s complete lack of participation in the legal proceedings, describing their conduct as dishonest and motivated by bad faith. The court ordered each defendant to compensate Blue Cross with costs amounting to ₹5 lakh, payable within eight weeks, with an 8% per annum interest penalty for non-compliance.
The legal representatives for Blue Cross included Advocates Siddhant Gupta, Prachi Shah, Apeksha Mehta, Rashi Thakur, and Vinod A Bhagat. This ruling serves as a deterrent to potential infringers and reinforces the protection of established trademarks.
